Avui, dilluns 8 de juny, el Dipòsit Digital no estarà operatiu de 15:00 a 17:00 h per tasques de manteniment. Disculpeu les molèsties.
Hoy, lunes 8 de junio, el Dipòsit Digital no estará operativo de 15:00 a 17:00 h debido a tareas de mantenimiento. Disculpen las molestias.
Today, Monday, Jun 8th, the Digital Repository will be unavailable due to a system update.

Document type

Article

Version

Published version

Publication date

Publication license

cc-by (c) Narváez García, Francisco Javier et al., 2024
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/216409

Moving forward in Rheumatoid Arthritis-Associated Interstitial Lung Disease Screening

Journal Title

Director/Tutor

Journal ISSN

Volume Title

Abstract

Patients with rheumatoid arthritis (RA) are at increased risk of developing interstitial lung disease compared to the general population, a complication that is associated with significant morbidity and high mortality. Given its frequency and severity, ILD should always be considered during both the initial assessment and follow-up of RA patients. However, there is currently no consensus on which RA patients should be screened for ILD. In recent years, several scientific societies have developed specific screening proposals. According to the recommendations of the Spanish, American, and Austrian rheumatology societies, it is not necessary to screen all individuals with RA, and it should be tailored to each patient based on clinical risk factors. In contrast, the Portuguese Societies of Rheumatology and Pulmonology advocate for systematic screening of all RA patients. Risk factors for the development of ILD in RA patients are well identified, and several screening tools for RA-ILD based on these risk factors have been developed. However, all of these tools still require further validation. To address this issue, the ANCHOR-RA study, a multinational cross-sectional initiative, has been launched to develop a multivariable model for predicting RA-ILD, which could provide valuable guidance for screening practices in clinical settings. In addition to certain biochemical and genetic predictive markers, lung ultrasound appears to be a useful screening tool. When combined with clinical evaluation and risk factor assessment, it can help identify which patients require a thoracic HRCT evaluation, which remains the gold standard for confirming an ILD diagnosis.

Citation

Citation

NARVÁEZ GARCÍA, Francisco Javier. Moving forward in Rheumatoid Arthritis-Associated Interstitial Lung Disease Screening. Journal of Clinical Medicine. 2024. Vol. 13, num. 18. ISSN 2077-0383. [consulted: 9 of June of 2026]. Available at: https://hdl.handle.net/2445/216409

Export metadata

JSON - METS

Share record